The CSNK2A1 antibody targets the alpha 1 catalytic subunit of Casein Kinase 2 (CK2), a ubiquitously expressed serine/threonine kinase involved in critical cellular processes, including proliferation, apoptosis, DNA repair, and signal transduction. CK2 exists as a heterotetrameric complex, typically composed of two catalytic subunits (α/α') and two regulatory β subunits. CSNK2A1 encodes the α subunit, which drives the kinase's enzymatic activity by phosphorylating diverse substrates, such as transcription factors, tumor suppressors, and signaling proteins. Dysregulation of CK2. particularly CSNK2A1 overexpression, is linked to cancer progression, neurodegenerative disorders, and inflammatory diseases, making it a potential therapeutic target.
Antibodies against CSNK2A1 are essential tools for studying its expression, localization, and function in normal and pathological contexts. They are widely used in techniques like Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF) to quantify protein levels, assess tissue-specific distribution, or investigate signaling pathways. Monoclonal and polyclonal variants exist, with validation depending on applications (e.g., specificity in knock-out models or cross-reactivity checks). Researchers also utilize these antibodies to explore CK2's role in modulating pathways like Wnt, NF-κB, and PI3K/Akt, providing insights into disease mechanisms and drug discovery. Reliable CSNK2A1 antibodies are critical for both basic research and translational studies aiming to target CK2 in precision medicine.